Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag
by Zacks Equity Research
Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
by Indrajit Bandyopadhyay
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease
by Zacks Equity Research
Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.
Editas (EDIT) Down on Initial Data From Eye Disease Study
by Zacks Equity Research
Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.
Implied Volatility Surging for Editas (EDIT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Editas (EDIT) stock based on the movements in the options market lately.
Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
by Zacks Equity Research
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch. However, sole dependence on Oxbryta for growth remains a concern.
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.
How Are Genomics ETFs Responding to Q2 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 4.71% and -94.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Editas (EDIT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) second-quarter earnings call, investor focus will likely be on the company's progress with the development of EDIT-101, its lead pipeline candidate.
Editas Medicine (EDIT) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $41.86, marking a -0.1% move from the previous day.
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Do Options Traders Know Something About Editas Medicine (EDIT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data
by Zacks Equity Research
Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.
3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data
by Zacks Equity Research
Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.
Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study
by Zacks Equity Research
Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.
AMC FUD Runneth Over: Panic at the Casino!
by Kevin Cook
Should AMC be worth over 5X what Amazon just paid for MGM Studios?
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.
Why Is Editas (EDIT) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.